DK2453914T3 - Antigenspecifikke multiepitopbaserede anti-infektiøse vacciner - Google Patents
Antigenspecifikke multiepitopbaserede anti-infektiøse vacciner Download PDFInfo
- Publication number
- DK2453914T3 DK2453914T3 DK10747083.3T DK10747083T DK2453914T3 DK 2453914 T3 DK2453914 T3 DK 2453914T3 DK 10747083 T DK10747083 T DK 10747083T DK 2453914 T3 DK2453914 T3 DK 2453914T3
- Authority
- DK
- Denmark
- Prior art keywords
- leu
- ala
- seq
- gly
- val
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (14)
1. Sammensætning, der omfatter et immunogent peptid eller et rekombinant polypeptid, der omfatter mindst ét signalpeptiddomæne, hvor signalpeptiddomænet består af SEQ ID NO: 12.
2. Sammensætning ifølge krav 1, der endvidere omfatter et signalpeptiddomæne, der omfatter en sekvens, der er udvalgt fra SEQ ID NO: 1-11 og 13-54.
3. Sammensætning ifølge krav 1, hvor sammensætningen endvidere omfatter mindst én aminosyresekvens, der er udvalgt fra gruppen bestående af SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 4, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 13 og SEQ ID NO. 15.
4. Sammensætning ifølge krav 1, hvor det rekombinante polypeptid består af aminosyresekvensen fra SEQ ID NO. 2, SEQ ID NO. 4, SEQ ID NO. 9, SEQ ID NO. 12 og SEQ ID NO. 13 adskilt af fleksible linkere.
5. Sammensætning ifølge krav 1, hvor det rekombinante polypeptid kodes for af et polynukleotid, der omfatter restriktionsenzymsteder.
6. Sammensætning ifølge krav 4, hvor det rekombinante polypeptid består af aminosyresekvensen fra SEQ ID NO: 55 eller en aminosyresekvens med mindst 85 % homologi med SEQ ID NO: 55.
7. Isoleret nukleinsyremolekyle, der omfatter en nukleotidsekvens, der koder for et peptid eller rekombinant polypeptid ifølge et hvilket som helst af kravene 1-6.
8. Nukleinsyrevaccine, der omfatter et nukleinsyremolekyle ifølge krav 7.
9. Isoleret antigenpræsenterende celle, der er forsynet med et immunogent peptid omfattende SEQ ID NO: 12.
10. Farmaceutisk sammensætning omfattende mindst én sammensætning ifølge et hvilket som helst af kravene 1-6 eller nukleinsyrevaccinen ifølge krav 8 eller den antigenpræsenterende celle ifølge krav 9 og et farmaceutisk acceptabelt bærestof eller fortyndingsmiddel.
11. Farmaceutisk sammensætning ifølge krav 10, der er indrettet til samtidig administration med anti-infektiøse midler.
12. Anvendelse af sammensætningen ifølge et hvilket som helst af kravene 1-6 eller nukleinsyrevaccinen ifølge krav 8 eller den antigenpræsenterende celle ifølge krav 9 til fremstilling af en farmaceutisk sammensætning til behandling eller forebyggelse af en tuberkuloseinfektion, eventuelt i kombination med andre anti-infektiøse midler.
13. Anvendelse af sammensætningen ifølge et hvilket som helst af kravene 1-6 til berigelse af en T-cellepopulation in vitro, hvorved der opnås en beriget T-cellepopulation, der responderer på sammensætningen.
14. Sammensætning ifølge et hvilket som helst af kravene 1-6 til anvendelse til generering af anti-tuberkulose-antistoffer hos et subjekt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22595709P | 2009-07-16 | 2009-07-16 | |
| PCT/IL2010/000569 WO2011007359A2 (en) | 2009-07-16 | 2010-07-15 | Antigen specific multi epitope -based anti-infective vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2453914T3 true DK2453914T3 (da) | 2018-10-08 |
Family
ID=43127671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10747083.3T DK2453914T3 (da) | 2009-07-16 | 2010-07-15 | Antigenspecifikke multiepitopbaserede anti-infektiøse vacciner |
Country Status (5)
| Country | Link |
|---|---|
| US (5) | US9642903B2 (da) |
| EP (1) | EP2453914B1 (da) |
| DK (1) | DK2453914T3 (da) |
| WO (1) | WO2011007359A2 (da) |
| ZA (1) | ZA201201137B (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011119484A1 (en) | 2010-03-23 | 2011-09-29 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| US20170039314A1 (en) * | 2010-03-23 | 2017-02-09 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| ES2586580T3 (es) | 2010-07-06 | 2016-10-17 | Glaxosmithkline Biologicals Sa | Inmunización de mamíferos grandes con dosis bajas de ARN |
| EP3243526B1 (en) | 2010-07-06 | 2019-11-27 | GlaxoSmithKline Biologicals S.A. | Delivery of rna to trigger multiple immune pathways |
| PT2590626E (pt) | 2010-07-06 | 2016-01-26 | Glaxosmithkline Biolog Sa | Lipossomas com lípidos que têm um valor de pka vantajoso para administração de arn |
| RS63983B1 (sr) | 2010-08-31 | 2023-03-31 | Glaxosmithkline Biologicals Sa | Pegilovani lipozomi za isporuku rnk koja kodira imunogen |
| TR201903651T4 (tr) | 2010-10-11 | 2019-04-22 | Glaxosmithkline Biologicals Sa | Antijen uygulama platformları. |
| CN109369795B (zh) * | 2018-11-14 | 2020-09-04 | 江南大学 | 一种调控巨噬细胞免疫功能活性的蛋白质及其应用 |
| WO2021181390A1 (en) * | 2020-03-09 | 2021-09-16 | Vaxil Biotherapeutics Ltd. | Antigen specific epitope–based anti-infective vaccines |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE4116249A1 (de) * | 1991-05-17 | 1992-11-19 | Biotechnolog Forschung Gmbh | Hybrid-plasmid fuer m.-tuberculosis-antigen, e. coli als wirt und antigen |
| EP0726941B1 (en) * | 1993-08-06 | 2002-04-03 | Epimmune Inc. | Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl |
| IL125608A0 (en) * | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| CA2438279A1 (en) * | 2001-02-22 | 2002-09-26 | Institut Pasteur | Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses |
| CA2665816C (en) | 2006-09-21 | 2016-07-12 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope vaccines |
| WO2008043180A1 (en) * | 2006-10-13 | 2008-04-17 | Zakaria Hmama | Immunostimulatory composition comprising recombinant bcg mycobacterium expressing mammalian cysteine protease |
-
2010
- 2010-07-15 US US13/384,286 patent/US9642903B2/en active Active
- 2010-07-15 DK DK10747083.3T patent/DK2453914T3/da active
- 2010-07-15 WO PCT/IL2010/000569 patent/WO2011007359A2/en active Application Filing
- 2010-07-15 EP EP10747083.3A patent/EP2453914B1/en active Active
-
2012
- 2012-02-16 ZA ZA2012/01137A patent/ZA201201137B/en unknown
-
2017
- 2017-05-08 US US15/588,887 patent/US10245309B2/en active Active
-
2019
- 2019-03-31 US US16/371,020 patent/US10350284B1/en active Active
- 2019-07-11 US US16/508,605 patent/US11135277B2/en active Active
-
2021
- 2021-09-30 US US17/490,498 patent/US20220111030A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20120177677A1 (en) | 2012-07-12 |
| US10350284B1 (en) | 2019-07-16 |
| EP2453914B1 (en) | 2018-09-05 |
| US11135277B2 (en) | 2021-10-05 |
| US20170354728A1 (en) | 2017-12-14 |
| US20220111030A1 (en) | 2022-04-14 |
| EP2453914A2 (en) | 2012-05-23 |
| US9642903B2 (en) | 2017-05-09 |
| US10245309B2 (en) | 2019-04-02 |
| US20190216912A1 (en) | 2019-07-18 |
| ZA201201137B (en) | 2012-10-31 |
| WO2011007359A3 (en) | 2011-07-07 |
| US20200061178A1 (en) | 2020-02-27 |
| WO2011007359A2 (en) | 2011-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11135277B2 (en) | Antigen specific multi epitope-based anti-infective vaccines | |
| KR102556485B1 (ko) | 신규 면역원성 펩티드 | |
| AU2007298494B2 (en) | Antigen specific multi epitope vaccines | |
| RU2682726C9 (ru) | Вакцинная композиция против злокачественной опухоли | |
| US20210283242A1 (en) | Immune-mediated coronavirus treatments | |
| RU2761653C2 (ru) | Пептиды и способы для лечения диабета | |
| KR20240015731A (ko) | 신규 면역원성 CD1d 결합 펩티드 | |
| Solioz et al. | The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis | |
| JPH08502244A (ja) | 免疫調節ペプチド | |
| CN107551264B (zh) | L3和/或l5源作为寄生虫病疫苗或诊断的用途 | |
| US5000952A (en) | Polypeptide pertussis toxin vaccine | |
| EP2987502B1 (en) | Peptide adjuvants | |
| US20190038740A1 (en) | MHC Class I Associated Hepatitis B Peptides | |
| US11559575B2 (en) | Multi-epitopic peptide compounds and vaccines against leishmaniasis | |
| KR20110060865A (ko) | 리슈마니아증 및 결핵에 대한 백신 개발을 위한 ｄｎａ 키메라의 작제 | |
| RU2539035C2 (ru) | Профилактическая или терапевтическая полиэпитопная противотуберкулезная вакцинная конструкция, обеспечивающая индукцию клеточного иммунного ответа cd4+ или cd8+ т-лимфоцитов | |
| US20020192229A1 (en) | MHC class I associated peptides for prevention and treatment of tuberculosis | |
| US20190255167A1 (en) | Fusion polypeptides | |
| FLYER et al. | Patent 2430896 Summary |